GLI1 and ovarian serous adenocarcinoma: While no differential changes in GLI1 were observed in our study, in another study, 56 primary advanced serous ovarian cancers and 12 normal ovarian tissues from postmenopausal women were immunohistochemically evaluated, and GLI1 immunoreactivity was absent from the surface epithelium and stromal cells of the normal ovaries; however, a positive nuclear reaction was observed in 29% of the serous ovarian carcinomas [32].